7-(3-(diethylamino)propoxy)-6-methoxyquinazolin-4(3H)-one | 1227264-00-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-(3-(diethylamino)propoxy)-6-methoxyquinazolin-4(3H)-one
• 英文别名: 7-(3-diethylaminopropoxy)-6-methoxy-4(3H)-quinazolinone
• CAS: 1227264-00-7
• 化学式: C₁₆H₂₃N₃O₃
• 分子量: 305.377
• InChiKey: XCGCRWWSDZCAPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.04
• 重原子数：
  22.0
• 可旋转键数：
  8.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  67.45
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  7-(3-(diethylamino)propoxy)-6-methoxyquinazolin-4(3H)-one 在 氯化亚砜 、 sodium hydride 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 生成 N-(2-chloro-6-methylphenyl)-2-(7-(3-(diethylamino)propoxy)-6-methoxyquinazolin-4-ylamino)benzo[d]thiazole-6-carboxamide
  参考文献：
  名称：

  Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents

  摘要：

  Three series of novel 4-benzothiazole amino quinazolines Dasatinib derivatives have been designed and synthesized. The entire target compounds were investigated for their in vitro cytotoxic activity by the MTT-based assay against 6 human cancer cell lines. Compared with the parental Dasatinib, most of the new compounds, especially 2, 4, 6-trimethylaniline series (3), demonstrated significant inhibitory activities against six cell lines. Furthermore, the target compounds were screened for Src and Abl kinase inhibitory activity. Among them, 1a, 1f and 3a-3f are more potential dual Src/Abl kinase inhibitors. Thus they may be promising lead compounds to be developed as an alternative for current Dasatinib therapy or for Imatinib-resistant patients, potentially via simultaneously blocking multiple RTK signaling pathways. (c) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.013
• 作为产物：
  描述：

  香草酸甲酯 在 硝酸 、 铁粉 、 potassium carbonate 、 potassium iodide 作用下， 以 乙醇 、 溶剂黄146 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.5h， 生成 7-(3-(diethylamino)propoxy)-6-methoxyquinazolin-4(3H)-one
  参考文献：
  名称：

  Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents

  摘要：

  Three series of novel 4-benzothiazole amino quinazolines Dasatinib derivatives have been designed and synthesized. The entire target compounds were investigated for their in vitro cytotoxic activity by the MTT-based assay against 6 human cancer cell lines. Compared with the parental Dasatinib, most of the new compounds, especially 2, 4, 6-trimethylaniline series (3), demonstrated significant inhibitory activities against six cell lines. Furthermore, the target compounds were screened for Src and Abl kinase inhibitory activity. Among them, 1a, 1f and 3a-3f are more potential dual Src/Abl kinase inhibitors. Thus they may be promising lead compounds to be developed as an alternative for current Dasatinib therapy or for Imatinib-resistant patients, potentially via simultaneously blocking multiple RTK signaling pathways. (c) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.013

文献信息

• 常山碱衍生物及其在制备抗耐药菌药物中的 应用
  申请人：广东工业大学

  公开号：CN103980251B

  公开（公告）日：2017-01-18

  本发明公开了一种常山碱衍生物及其在制备抗耐药菌药物中的应用，通过试验表明，本发明的常山碱衍生物在体外能抑制多种耐药菌的繁殖，可用于制备抗耐药菌的抗生素药物；如应用在制备抗耐甲氧西林金黄葡萄菌的药物，制备抗耐氨苄青霉素金黄色葡萄球菌的药物，制备抗耐万古霉素肠球菌的药物；该药物制成注射剂、片剂、丸剂、胶囊、悬浮剂或乳剂的形式使用，所述的常山碱衍生物的化学结构式如式Ⅰ所示，式中R1、R2、R3、R4如说明书所定义。